Expression of PDK‑1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance

Sun,Zhichao; Xu,Lei

doi:10.3892/ol.2019.10639

Expression of PDK‑1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance

Authors:
- Zhichao Sun
- Lei Xu
View Affiliations

Affiliations: Department of Pathology, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China
Published online on: July 18, 2019 https://doi.org/10.3892/ol.2019.10639
Pages: 2819-2824
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was designed to explore the expression of phosphoinositide‑dependent protein kinase 1 (PDK‑1), deleted in malignant brain tumors (DMBT1) in the thyroid carcinoma. A total of 87 fresh samples of thyroid carcinoma from surgical resection in The Second People's Hospital of Lianyungang from June 2016 to March 2018 were collected for the ELISA to detect the protein expression of PDK‑1 and DMBT1. Then the pathological significance of the expression of PDK‑1 and DMBT1 in the thyroid carcinoma and the correlation between them were analyzed, using the ROC curve to study the diagnostic value of each index. The expression of PDK‑1 in the thyroid carcinoma tissue was significantly higher than that in the normal thyroid tissue with a statistical difference between them (P<0.05); the expression of DMBT1 in the thyroid carcinoma was statistically significantly lower than that in the normal thyroid tissue (P<0.05); the PDK‑1 and DMBT1 expressions were in negative correlation in the thyroid carcinoma (r=-0.889, P<0.001). The AUG, specificity and the sensitivity of the PDK‑1 in diagnosing the thyroid carcinoma were 0.862, 86.21% and 78.16%, respectively; the AUG, specificity and the sensitivity of the DMBT1 in diagnosing the thyroid carcinoma were 0.708, 66.67% and 67.82%, respectively; while the AUG, the specificity and the sensitivity of the combination of PDK‑1 and DMBT1 in diagnosing the thyroid carcinoma were 0.888, 89.66% and 81.61%. In conclusion, the occurrence and progression of the thyroid carcinoma were related to the high expression of the PDK‑1 and the low expression of the DMBT1 in the thyroid carcinoma tissues, the two of which were in connection with factors involving lymph node metastasis, pathological type, neoplasm staging, and clinical staging. Thus, the combined detection of PDK‑1 and DMBT1 could be used as an effective index to determine the occurrence of thyroid carcinoma.

View Figures

View References

1	Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Jabbour E, Deininger M and Hochhaus A: Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 25:201–210. 2011. View Article : Google Scholar : PubMed/NCBI
5	Braidotti P, Nuciforo PG, Mollenhauer J, Poustka A, Pellegrini C, Moro A, Bulfamante G, Coggi G, Bosari S and Pietra GG: DMBT1 expression is down-regulated in breast cancer. BMC Cancer. 4:462004. View Article : Google Scholar : PubMed/NCBI
6	Imai MA, Moriya T, Imai FL, Shiiba M, Bukawa H, Yokoe H, Uzawa K and Tanzawa H: Down-regulation of DMBT1 gene expression in human oral squamous cell carcinoma. Int J Mol Med. 15:585–589. 2005.PubMed/NCBI
7	Hernandez BY, Green MD, Cassel KD, Pobutsky AM, Vu V and Wilkens LR: Preview of Hawaii cancer facts and figures 2010. Hawaii Med J. 69:223–224. 2010.PubMed/NCBI
8	Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
9	Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
10	Gagliardi PA, Puliafito A and Primo L: PDK1: At the crossroad of cancer signaling pathways. Semin Cancer Biol. 48:27–35. 2018. View Article : Google Scholar : PubMed/NCBI
11	Leroux AE, Schulze JO and Biondi RM: AGC kinases, mechanisms of regulation and innovative drug development. Semin Cancer Biol. 48:1–17. 2018. View Article : Google Scholar : PubMed/NCBI
12	Arsenic R: Immunohistochemical analysis of PDK1 expression in breast cancer. Diagn Pathol. 9:822014. View Article : Google Scholar : PubMed/NCBI
13	Han L, Zhang G, Zhang N, Li H, Liu Y, Fu A and Zheng Y: Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol. 31:1292014. View Article : Google Scholar : PubMed/NCBI
14	Ferro R and Falasca M: Emerging role of the KRAS-PDK1 axis in pancreatic cancer. World J Gastroenterol. 20:10752–10757. 2014. View Article : Google Scholar : PubMed/NCBI
15	Zheng N, Ding X, Sun A and Jahan R: PDK1 activity regulates proliferation, invasion and growth of hemangiomas. Cell Physiol Biochem. 36:1903–1910. 2015. View Article : Google Scholar : PubMed/NCBI
16	Lian S, Shao Y, Liu H, He J, Lu W, Zhang Y, Jiang Y and Zhu J: PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer. Oncotarget. 6:29076–29086. 2015. View Article : Google Scholar : PubMed/NCBI
17	Mollenhauer J, Holmskov U, Wiemann S, Krebs I, Herbertz S, Madsen J, Kioschis P, Coy JF and Poustka A: The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability. Oncogene. 18:6233–6240. 1999. View Article : Google Scholar : PubMed/NCBI
18	Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A and Poustka A: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours. Nat Genet. 17:32–39. 1997. View Article : Google Scholar : PubMed/NCBI
19	Smith HA and Kang Y: The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl). 91:411–429. 2013. View Article : Google Scholar : PubMed/NCBI
20	Deng H, Gao YB, Wang HF, Jin XL and Xiao JC: Expression of deleted in malignant brain tumours 1 (DMBT1) relates to the proliferation and malignant transformation of hepatic progenitor cells in hepatitis B virus-related liver diseases. Histopathology. 60:249–260. 2012. View Article : Google Scholar : PubMed/NCBI
21	Du J, Guan M, Fan J and Jiang H: Loss of DMBT1 expression in human prostate cancer and its correlation with clinical progressive features. Urology. 77:509.e9–509.e13. 2011. View Article : Google Scholar
22	Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61:249–255. 2001.PubMed/NCBI
23	Mollenhauer J, Herbertz S, Helmke B, Kollender G, Krebs I, Madsen J, Holmskov U, Sorger K, Schmitt L, Wiemann S, et al: Deleted in Malignant Brain Tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer. Cancer Res. 61:8880–8886. 2001.PubMed/NCBI
24	Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, Young HA, Trinchieri G and Wink DA: Molecular pathways: toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity. Clin Cancer Res. 19:1340–1346. 2013. View Article : Google Scholar : PubMed/NCBI